nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—Formoterol—chronic obstructive pulmonary disease	0.19	0.5	CrCtD
Labetalol—Arformoterol—chronic obstructive pulmonary disease	0.19	0.5	CrCtD
Labetalol—ADRB2—chronic obstructive pulmonary disease	0.138	1	CbGaD
Labetalol—ADRB2—Salbutamol—chronic obstructive pulmonary disease	0.0358	0.18	CbGbCtD
Labetalol—ADRB1—Salbutamol—chronic obstructive pulmonary disease	0.0353	0.178	CbGbCtD
Labetalol—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0271	0.137	CbGbCtD
Labetalol—ADRB2—Arformoterol—chronic obstructive pulmonary disease	0.0271	0.137	CbGbCtD
Labetalol—ADRB1—Formoterol—chronic obstructive pulmonary disease	0.0267	0.135	CbGbCtD
Labetalol—ADRB1—Arformoterol—chronic obstructive pulmonary disease	0.0267	0.135	CbGbCtD
Labetalol—Formoterol—Arformoterol—chronic obstructive pulmonary disease	0.0248	0.101	CrCrCtD
Labetalol—Arformoterol—Formoterol—chronic obstructive pulmonary disease	0.0248	0.101	CrCrCtD
Labetalol—Salmeterol—Salbutamol—chronic obstructive pulmonary disease	0.0246	0.1	CrCrCtD
Labetalol—Dobutamine—Formoterol—chronic obstructive pulmonary disease	0.0223	0.0908	CrCrCtD
Labetalol—Dobutamine—Arformoterol—chronic obstructive pulmonary disease	0.0223	0.0908	CrCrCtD
Labetalol—Fenoterol—Arformoterol—chronic obstructive pulmonary disease	0.0173	0.0704	CrCrCtD
Labetalol—Ritodrine—Formoterol—chronic obstructive pulmonary disease	0.0173	0.0704	CrCrCtD
Labetalol—Fenoterol—Formoterol—chronic obstructive pulmonary disease	0.0173	0.0704	CrCrCtD
Labetalol—Ritodrine—Arformoterol—chronic obstructive pulmonary disease	0.0173	0.0704	CrCrCtD
Labetalol—Arbutamine—Arformoterol—chronic obstructive pulmonary disease	0.0151	0.0616	CrCrCtD
Labetalol—Arbutamine—Formoterol—chronic obstructive pulmonary disease	0.0151	0.0616	CrCrCtD
Labetalol—Isoprenaline—Arformoterol—chronic obstructive pulmonary disease	0.00993	0.0404	CrCrCtD
Labetalol—Isoprenaline—Formoterol—chronic obstructive pulmonary disease	0.00993	0.0404	CrCrCtD
Labetalol—Isoprenaline—Salbutamol—chronic obstructive pulmonary disease	0.00752	0.0306	CrCrCtD
Labetalol—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0068	0.0343	CbGbCtD
Labetalol—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0068	0.0343	CbGbCtD
Labetalol—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.00606	0.0306	CbGbCtD
Labetalol—ADRB3—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.000354	0.0929	CbGpPWpGaD
Labetalol—ADRB1—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.00021	0.0551	CbGpPWpGaD
Labetalol—Salmeterol—ADRB2—chronic obstructive pulmonary disease	0.000128	0.0876	CrCbGaD
Labetalol—ADRB3—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000125	0.0328	CbGpPWpGaD
Labetalol—Quinapril—ACE—chronic obstructive pulmonary disease	0.000124	0.0846	CrCbGaD
Labetalol—Fenoterol—ADRB2—chronic obstructive pulmonary disease	0.000123	0.0843	CrCbGaD
Labetalol—Ritodrine—ADRB2—chronic obstructive pulmonary disease	0.000123	0.0843	CrCbGaD
Labetalol—Arbutamine—ADRB2—chronic obstructive pulmonary disease	0.000115	0.0789	CrCbGaD
Labetalol—Formoterol—ADRB2—chronic obstructive pulmonary disease	0.000112	0.0766	CrCbGaD
Labetalol—Arformoterol—ADRB2—chronic obstructive pulmonary disease	0.000112	0.0766	CrCbGaD
Labetalol—Benazepril—ACE—chronic obstructive pulmonary disease	0.000108	0.0736	CrCbGaD
Labetalol—Dobutamine—ADRB2—chronic obstructive pulmonary disease	0.000106	0.0726	CrCbGaD
Labetalol—ADRB3—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000105	0.0276	CbGpPWpGaD
Labetalol—Hypoaesthesia—Salbutamol—chronic obstructive pulmonary disease	0.0001	0.00303	CcSEcCtD
Labetalol—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	9.98e-05	0.00301	CcSEcCtD
Labetalol—Hypertension—Tiotropium—chronic obstructive pulmonary disease	9.96e-05	0.003	CcSEcCtD
Labetalol—Dizziness—Roflumilast—chronic obstructive pulmonary disease	9.9e-05	0.00298	CcSEcCtD
Labetalol—Shock—Aminophylline—chronic obstructive pulmonary disease	9.82e-05	0.00296	CcSEcCtD
Labetalol—ADRB3—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	9.79e-05	0.0257	CbGpPWpGaD
Labetalol—Vomiting—Roflumilast—chronic obstructive pulmonary disease	9.52e-05	0.00287	CcSEcCtD
Labetalol—ADRB1—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	9.5e-05	0.0249	CbGpPWpGaD
Labetalol—Rash—Roflumilast—chronic obstructive pulmonary disease	9.44e-05	0.00285	CcSEcCtD
Labetalol—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	9.43e-05	0.00284	CcSEcCtD
Labetalol—Oedema—Tiotropium—chronic obstructive pulmonary disease	9.41e-05	0.00284	CcSEcCtD
Labetalol—Headache—Roflumilast—chronic obstructive pulmonary disease	9.38e-05	0.00283	CcSEcCtD
Labetalol—Flushing—Salbutamol—chronic obstructive pulmonary disease	9.37e-05	0.00283	CcSEcCtD
Labetalol—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	9.37e-05	0.00282	CcSEcCtD
Labetalol—Mental disorder—Formoterol—chronic obstructive pulmonary disease	9.37e-05	0.00282	CcSEcCtD
Labetalol—Hypotension—Aminophylline—chronic obstructive pulmonary disease	9.33e-05	0.00281	CcSEcCtD
Labetalol—Shock—Tiotropium—chronic obstructive pulmonary disease	9.26e-05	0.00279	CcSEcCtD
Labetalol—Mental disorder—Montelukast—chronic obstructive pulmonary disease	9.18e-05	0.00277	CcSEcCtD
Labetalol—Ketoprofen—CXCL8—chronic obstructive pulmonary disease	9.08e-05	0.062	CrCbGaD
Labetalol—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	8.95e-05	0.0027	CcSEcCtD
Labetalol—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	8.95e-05	0.0027	CcSEcCtD
Labetalol—Nausea—Roflumilast—chronic obstructive pulmonary disease	8.89e-05	0.00268	CcSEcCtD
Labetalol—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	8.85e-05	0.00267	CcSEcCtD
Labetalol—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	8.79e-05	0.00265	CcSEcCtD
Labetalol—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	8.77e-05	0.00264	CcSEcCtD
Labetalol—Tremor—Formoterol—chronic obstructive pulmonary disease	8.72e-05	0.00263	CcSEcCtD
Labetalol—Tremor—Arformoterol—chronic obstructive pulmonary disease	8.72e-05	0.00263	CcSEcCtD
Labetalol—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	8.65e-05	0.00261	CcSEcCtD
Labetalol—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	8.64e-05	0.0026	CcSEcCtD
Labetalol—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	8.64e-05	0.0026	CcSEcCtD
Labetalol—ADRB3—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	8.59e-05	0.0225	CbGpPWpGaD
Labetalol—Tremor—Montelukast—chronic obstructive pulmonary disease	8.54e-05	0.00258	CcSEcCtD
Labetalol—Angioedema—Arformoterol—chronic obstructive pulmonary disease	8.51e-05	0.00256	CcSEcCtD
Labetalol—Angioedema—Formoterol—chronic obstructive pulmonary disease	8.51e-05	0.00256	CcSEcCtD
Labetalol—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	8.45e-05	0.00255	CcSEcCtD
Labetalol—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	8.45e-05	0.00255	CcSEcCtD
Labetalol—Malaise—Formoterol—chronic obstructive pulmonary disease	8.4e-05	0.00253	CcSEcCtD
Labetalol—Malaise—Arformoterol—chronic obstructive pulmonary disease	8.4e-05	0.00253	CcSEcCtD
Labetalol—Angioedema—Montelukast—chronic obstructive pulmonary disease	8.33e-05	0.00251	CcSEcCtD
Labetalol—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	8.29e-05	0.0025	CcSEcCtD
Labetalol—Affect lability—Prednisolone—chronic obstructive pulmonary disease	8.24e-05	0.00248	CcSEcCtD
Labetalol—Tremor—Salbutamol—chronic obstructive pulmonary disease	8.24e-05	0.00248	CcSEcCtD
Labetalol—ADRB3—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	8.23e-05	0.0216	CbGpPWpGaD
Labetalol—Palpitations—Arformoterol—chronic obstructive pulmonary disease	8.23e-05	0.00248	CcSEcCtD
Labetalol—Palpitations—Formoterol—chronic obstructive pulmonary disease	8.23e-05	0.00248	CcSEcCtD
Labetalol—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	8.16e-05	0.00246	CcSEcCtD
Labetalol—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	8.16e-05	0.00246	CcSEcCtD
Labetalol—Palpitations—Montelukast—chronic obstructive pulmonary disease	8.06e-05	0.00243	CcSEcCtD
Labetalol—Constipation—Tiotropium—chronic obstructive pulmonary disease	8.05e-05	0.00243	CcSEcCtD
Labetalol—Hypertension—Arformoterol—chronic obstructive pulmonary disease	8.04e-05	0.00242	CcSEcCtD
Labetalol—Hypertension—Formoterol—chronic obstructive pulmonary disease	8.04e-05	0.00242	CcSEcCtD
Labetalol—Angioedema—Salbutamol—chronic obstructive pulmonary disease	8.03e-05	0.00242	CcSEcCtD
Labetalol—Mood swings—Prednisolone—chronic obstructive pulmonary disease	7.93e-05	0.00239	CcSEcCtD
Labetalol—Urticaria—Aminophylline—chronic obstructive pulmonary disease	7.93e-05	0.00239	CcSEcCtD
Labetalol—Malaise—Salbutamol—chronic obstructive pulmonary disease	7.93e-05	0.00239	CcSEcCtD
Labetalol—Vertigo—Salbutamol—chronic obstructive pulmonary disease	7.9e-05	0.00238	CcSEcCtD
Labetalol—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	7.89e-05	0.00238	CcSEcCtD
Labetalol—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	7.89e-05	0.00238	CcSEcCtD
Labetalol—Syncope—Salbutamol—chronic obstructive pulmonary disease	7.88e-05	0.00238	CcSEcCtD
Labetalol—Discomfort—Formoterol—chronic obstructive pulmonary disease	7.83e-05	0.00236	CcSEcCtD
Labetalol—Discomfort—Arformoterol—chronic obstructive pulmonary disease	7.83e-05	0.00236	CcSEcCtD
Labetalol—Palpitations—Salbutamol—chronic obstructive pulmonary disease	7.77e-05	0.00234	CcSEcCtD
Labetalol—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	7.73e-05	0.00233	CcSEcCtD
Labetalol—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	7.7e-05	0.00232	CcSEcCtD
Labetalol—Oedema—Formoterol—chronic obstructive pulmonary disease	7.6e-05	0.00229	CcSEcCtD
Labetalol—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	7.6e-05	0.00229	CcSEcCtD
Labetalol—Oedema—Arformoterol—chronic obstructive pulmonary disease	7.6e-05	0.00229	CcSEcCtD
Labetalol—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	7.6e-05	0.00229	CcSEcCtD
Labetalol—Hypertension—Salbutamol—chronic obstructive pulmonary disease	7.59e-05	0.00229	CcSEcCtD
Labetalol—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	7.49e-05	0.0196	CbGpPWpGaD
Labetalol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	7.48e-05	0.00225	CcSEcCtD
Labetalol—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	7.44e-05	0.00224	CcSEcCtD
Labetalol—Oedema—Montelukast—chronic obstructive pulmonary disease	7.44e-05	0.00224	CcSEcCtD
Labetalol—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	7.44e-05	0.00224	CcSEcCtD
Labetalol—ADRB1—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	7.43e-05	0.0195	CbGpPWpGaD
Labetalol—Discomfort—Salbutamol—chronic obstructive pulmonary disease	7.39e-05	0.00223	CcSEcCtD
Labetalol—ADRB1—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	7.37e-05	0.0193	CbGpPWpGaD
Labetalol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	7.36e-05	0.00222	CcSEcCtD
Labetalol—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	7.17e-05	0.00216	CcSEcCtD
Labetalol—Oedema—Salbutamol—chronic obstructive pulmonary disease	7.17e-05	0.00216	CcSEcCtD
Labetalol—Hypotension—Arformoterol—chronic obstructive pulmonary disease	7.1e-05	0.00214	CcSEcCtD
Labetalol—Hypotension—Formoterol—chronic obstructive pulmonary disease	7.1e-05	0.00214	CcSEcCtD
Labetalol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	7.06e-05	0.00213	CcSEcCtD
Labetalol—Shock—Salbutamol—chronic obstructive pulmonary disease	7.06e-05	0.00213	CcSEcCtD
Labetalol—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	7.05e-05	0.00212	CcSEcCtD
Labetalol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	6.94e-05	0.00209	CcSEcCtD
Labetalol—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	6.94e-05	0.00209	CcSEcCtD
Labetalol—ADRB1—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	6.9e-05	0.0181	CbGpPWpGaD
Labetalol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	6.83e-05	0.00206	CcSEcCtD
Labetalol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	6.77e-05	0.00204	CcSEcCtD
Labetalol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	6.77e-05	0.00204	CcSEcCtD
Labetalol—Somnolence—Formoterol—chronic obstructive pulmonary disease	6.75e-05	0.00204	CcSEcCtD
Labetalol—Somnolence—Arformoterol—chronic obstructive pulmonary disease	6.75e-05	0.00204	CcSEcCtD
Labetalol—Hypotension—Salbutamol—chronic obstructive pulmonary disease	6.7e-05	0.00202	CcSEcCtD
Labetalol—Mirabegron—ALB—chronic obstructive pulmonary disease	6.7e-05	0.0457	CrCbGaD
Labetalol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	6.69e-05	0.00202	CcSEcCtD
Labetalol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	6.69e-05	0.00202	CcSEcCtD
Labetalol—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	6.68e-05	0.00201	CcSEcCtD
Labetalol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	6.66e-05	0.00201	CcSEcCtD
Labetalol—ADRB1—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	6.64e-05	0.0174	CbGpPWpGaD
Labetalol—Somnolence—Montelukast—chronic obstructive pulmonary disease	6.62e-05	0.00199	CcSEcCtD
Labetalol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	6.6e-05	0.00199	CcSEcCtD
Labetalol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	6.55e-05	0.00197	CcSEcCtD
Labetalol—Fatigue—Formoterol—chronic obstructive pulmonary disease	6.55e-05	0.00197	CcSEcCtD
Labetalol—Fatigue—Arformoterol—chronic obstructive pulmonary disease	6.55e-05	0.00197	CcSEcCtD
Labetalol—Constipation—Arformoterol—chronic obstructive pulmonary disease	6.5e-05	0.00196	CcSEcCtD
Labetalol—Pain—Arformoterol—chronic obstructive pulmonary disease	6.5e-05	0.00196	CcSEcCtD
Labetalol—Pain—Formoterol—chronic obstructive pulmonary disease	6.5e-05	0.00196	CcSEcCtD
Labetalol—Constipation—Formoterol—chronic obstructive pulmonary disease	6.5e-05	0.00196	CcSEcCtD
Labetalol—Amnesia—Prednisone—chronic obstructive pulmonary disease	6.48e-05	0.00195	CcSEcCtD
Labetalol—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	6.44e-05	0.00194	CcSEcCtD
Labetalol—Fatigue—Montelukast—chronic obstructive pulmonary disease	6.42e-05	0.00193	CcSEcCtD
Labetalol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	6.4e-05	0.00193	CcSEcCtD
Labetalol—Somnolence—Salbutamol—chronic obstructive pulmonary disease	6.38e-05	0.00192	CcSEcCtD
Labetalol—Pain—Montelukast—chronic obstructive pulmonary disease	6.36e-05	0.00192	CcSEcCtD
Labetalol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	6.35e-05	0.00191	CcSEcCtD
Labetalol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	6.32e-05	0.0019	CcSEcCtD
Labetalol—Rash—Aminophylline—chronic obstructive pulmonary disease	6.29e-05	0.0019	CcSEcCtD
Labetalol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	6.29e-05	0.0019	CcSEcCtD
Labetalol—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	6.26e-05	0.0164	CbGpPWpGaD
Labetalol—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	6.26e-05	0.00189	CcSEcCtD
Labetalol—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	6.26e-05	0.00189	CcSEcCtD
Labetalol—Headache—Aminophylline—chronic obstructive pulmonary disease	6.25e-05	0.00189	CcSEcCtD
Labetalol—ADRB1—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	6.25e-05	0.0164	CbGpPWpGaD
Labetalol—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	6.23e-05	0.00188	CcSEcCtD
Labetalol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	6.23e-05	0.00188	CcSEcCtD
Labetalol—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	6.21e-05	0.00187	CcSEcCtD
Labetalol—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	6.21e-05	0.00187	CcSEcCtD
Labetalol—Lethargy—Prednisone—chronic obstructive pulmonary disease	6.21e-05	0.00187	CcSEcCtD
Labetalol—Fatigue—Salbutamol—chronic obstructive pulmonary disease	6.19e-05	0.00186	CcSEcCtD
Labetalol—Constipation—Salbutamol—chronic obstructive pulmonary disease	6.13e-05	0.00185	CcSEcCtD
Labetalol—Pain—Salbutamol—chronic obstructive pulmonary disease	6.13e-05	0.00185	CcSEcCtD
Labetalol—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	6.09e-05	0.00183	CcSEcCtD
Labetalol—Urticaria—Arformoterol—chronic obstructive pulmonary disease	6.04e-05	0.00182	CcSEcCtD
Labetalol—Urticaria—Formoterol—chronic obstructive pulmonary disease	6.04e-05	0.00182	CcSEcCtD
Labetalol—Isoprenaline—ADRB2—chronic obstructive pulmonary disease	6.03e-05	0.0412	CrCbGaD
Labetalol—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	6.02e-05	0.0158	CbGpPWpGaD
Labetalol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	6.01e-05	0.00181	CcSEcCtD
Labetalol—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	6.01e-05	0.00181	CcSEcCtD
Labetalol—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	6.01e-05	0.00181	CcSEcCtD
Labetalol—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	6.01e-05	0.00181	CcSEcCtD
Labetalol—Affect lability—Prednisone—chronic obstructive pulmonary disease	5.99e-05	0.00181	CcSEcCtD
Labetalol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	5.99e-05	0.0018	CcSEcCtD
Labetalol—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	5.94e-05	0.00179	CcSEcCtD
Labetalol—Rash—Tiotropium—chronic obstructive pulmonary disease	5.94e-05	0.00179	CcSEcCtD
Labetalol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	5.93e-05	0.00179	CcSEcCtD
Labetalol—Nausea—Aminophylline—chronic obstructive pulmonary disease	5.93e-05	0.00179	CcSEcCtD
Labetalol—Urticaria—Montelukast—chronic obstructive pulmonary disease	5.91e-05	0.00178	CcSEcCtD
Labetalol—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	5.91e-05	0.00178	CcSEcCtD
Labetalol—Headache—Tiotropium—chronic obstructive pulmonary disease	5.9e-05	0.00178	CcSEcCtD
Labetalol—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	5.9e-05	0.00178	CcSEcCtD
Labetalol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	5.88e-05	0.00177	CcSEcCtD
Labetalol—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	5.88e-05	0.00177	CcSEcCtD
Labetalol—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	5.87e-05	0.00177	CcSEcCtD
Labetalol—ADRB1—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	5.81e-05	0.0152	CbGpPWpGaD
Labetalol—Mood swings—Prednisone—chronic obstructive pulmonary disease	5.76e-05	0.00174	CcSEcCtD
Labetalol—Urticaria—Salbutamol—chronic obstructive pulmonary disease	5.7e-05	0.00172	CcSEcCtD
Labetalol—ADRB2—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	5.68e-05	0.0149	CbGpPWpGaD
Labetalol—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	5.67e-05	0.00171	CcSEcCtD
Labetalol—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	5.67e-05	0.00171	CcSEcCtD
Labetalol—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	5.6e-05	0.00169	CcSEcCtD
Labetalol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	5.6e-05	0.00169	CcSEcCtD
Labetalol—Nausea—Tiotropium—chronic obstructive pulmonary disease	5.59e-05	0.00169	CcSEcCtD
Labetalol—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	5.58e-05	0.00168	CcSEcCtD
Labetalol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	5.48e-05	0.00165	CcSEcCtD
Labetalol—Asthenia—Arformoterol—chronic obstructive pulmonary disease	5.45e-05	0.00164	CcSEcCtD
Labetalol—Asthenia—Formoterol—chronic obstructive pulmonary disease	5.45e-05	0.00164	CcSEcCtD
Labetalol—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	5.44e-05	0.0143	CbGpPWpGaD
Labetalol—Pruritus—Formoterol—chronic obstructive pulmonary disease	5.38e-05	0.00162	CcSEcCtD
Labetalol—Pruritus—Arformoterol—chronic obstructive pulmonary disease	5.38e-05	0.00162	CcSEcCtD
Labetalol—Asthenia—Montelukast—chronic obstructive pulmonary disease	5.34e-05	0.00161	CcSEcCtD
Labetalol—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	5.29e-05	0.00159	CcSEcCtD
Labetalol—Pruritus—Montelukast—chronic obstructive pulmonary disease	5.27e-05	0.00159	CcSEcCtD
Labetalol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	5.2e-05	0.00157	CcSEcCtD
Labetalol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	5.2e-05	0.00157	CcSEcCtD
Labetalol—Propafenone—CYP1A2—chronic obstructive pulmonary disease	5.18e-05	0.0354	CrCbGaD
Labetalol—Isoprenaline—CYP1A1—chronic obstructive pulmonary disease	5.17e-05	0.0353	CrCbGaD
Labetalol—ADRB2—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	5.15e-05	0.0135	CbGpPWpGaD
Labetalol—Asthenia—Salbutamol—chronic obstructive pulmonary disease	5.15e-05	0.00155	CcSEcCtD
Labetalol—Sweating increased—Prednisone—chronic obstructive pulmonary disease	5.12e-05	0.00154	CcSEcCtD
Labetalol—ADRB1—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	5.1e-05	0.0134	CbGpPWpGaD
Labetalol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	5.09e-05	0.00154	CcSEcCtD
Labetalol—Pruritus—Salbutamol—chronic obstructive pulmonary disease	5.08e-05	0.00153	CcSEcCtD
Labetalol—Erythema—Prednisolone—chronic obstructive pulmonary disease	5.04e-05	0.00152	CcSEcCtD
Labetalol—Dizziness—Formoterol—chronic obstructive pulmonary disease	5.02e-05	0.00151	CcSEcCtD
Labetalol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	5.02e-05	0.00151	CcSEcCtD
Labetalol—ADRB2—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	4.99e-05	0.0131	CbGpPWpGaD
Labetalol—Dizziness—Montelukast—chronic obstructive pulmonary disease	4.92e-05	0.00148	CcSEcCtD
Labetalol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	4.91e-05	0.00148	CcSEcCtD
Labetalol—ADRB1—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	4.88e-05	0.0128	CbGpPWpGaD
Labetalol—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	4.84e-05	0.00146	CcSEcCtD
Labetalol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	4.83e-05	0.00146	CcSEcCtD
Labetalol—Vomiting—Formoterol—chronic obstructive pulmonary disease	4.83e-05	0.00146	CcSEcCtD
Labetalol—Rash—Arformoterol—chronic obstructive pulmonary disease	4.79e-05	0.00144	CcSEcCtD
Labetalol—Rash—Formoterol—chronic obstructive pulmonary disease	4.79e-05	0.00144	CcSEcCtD
Labetalol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	4.79e-05	0.00144	CcSEcCtD
Labetalol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	4.79e-05	0.00144	CcSEcCtD
Labetalol—ADRB2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	4.78e-05	0.0125	CbGpPWpGaD
Labetalol—Headache—Formoterol—chronic obstructive pulmonary disease	4.76e-05	0.00143	CcSEcCtD
Labetalol—Headache—Arformoterol—chronic obstructive pulmonary disease	4.76e-05	0.00143	CcSEcCtD
Labetalol—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	4.75e-05	0.00143	CcSEcCtD
Labetalol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	4.74e-05	0.00143	CcSEcCtD
Labetalol—Vomiting—Montelukast—chronic obstructive pulmonary disease	4.73e-05	0.00143	CcSEcCtD
Labetalol—Rash—Montelukast—chronic obstructive pulmonary disease	4.69e-05	0.00141	CcSEcCtD
Labetalol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	4.69e-05	0.00141	CcSEcCtD
Labetalol—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	4.68e-05	0.00141	CcSEcCtD
Labetalol—Depression—Prednisone—chronic obstructive pulmonary disease	4.67e-05	0.00141	CcSEcCtD
Labetalol—Headache—Montelukast—chronic obstructive pulmonary disease	4.66e-05	0.00141	CcSEcCtD
Labetalol—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	4.65e-05	0.0122	CbGpPWpGaD
Labetalol—Angioedema—Prednisolone—chronic obstructive pulmonary disease	4.61e-05	0.00139	CcSEcCtD
Labetalol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	4.56e-05	0.00138	CcSEcCtD
Labetalol—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	4.55e-05	0.0119	CbGpPWpGaD
Labetalol—Malaise—Prednisolone—chronic obstructive pulmonary disease	4.55e-05	0.00137	CcSEcCtD
Labetalol—Vertigo—Prednisolone—chronic obstructive pulmonary disease	4.53e-05	0.00137	CcSEcCtD
Labetalol—Rash—Salbutamol—chronic obstructive pulmonary disease	4.52e-05	0.00136	CcSEcCtD
Labetalol—Syncope—Prednisolone—chronic obstructive pulmonary disease	4.52e-05	0.00136	CcSEcCtD
Labetalol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	4.52e-05	0.00136	CcSEcCtD
Labetalol—Nausea—Arformoterol—chronic obstructive pulmonary disease	4.51e-05	0.00136	CcSEcCtD
Labetalol—Nausea—Formoterol—chronic obstructive pulmonary disease	4.51e-05	0.00136	CcSEcCtD
Labetalol—Headache—Salbutamol—chronic obstructive pulmonary disease	4.49e-05	0.00135	CcSEcCtD
Labetalol—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	4.43e-05	0.00134	CcSEcCtD
Labetalol—Nausea—Montelukast—chronic obstructive pulmonary disease	4.42e-05	0.00133	CcSEcCtD
Labetalol—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	4.38e-05	0.0115	CbGpPWpGaD
Labetalol—Hypertension—Prednisolone—chronic obstructive pulmonary disease	4.35e-05	0.00131	CcSEcCtD
Labetalol—ADRB3—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	4.34e-05	0.0114	CbGpPWpGaD
Labetalol—Bradycardia—Prednisone—chronic obstructive pulmonary disease	4.28e-05	0.00129	CcSEcCtD
Labetalol—Nausea—Salbutamol—chronic obstructive pulmonary disease	4.26e-05	0.00128	CcSEcCtD
Labetalol—Discomfort—Prednisolone—chronic obstructive pulmonary disease	4.24e-05	0.00128	CcSEcCtD
Labetalol—Hallucination—Prednisone—chronic obstructive pulmonary disease	4.19e-05	0.00126	CcSEcCtD
Labetalol—Oedema—Prednisolone—chronic obstructive pulmonary disease	4.11e-05	0.00124	CcSEcCtD
Labetalol—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	4.11e-05	0.00124	CcSEcCtD
Labetalol—Shock—Prednisolone—chronic obstructive pulmonary disease	4.05e-05	0.00122	CcSEcCtD
Labetalol—ADRB1—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	4.05e-05	0.0106	CbGpPWpGaD
Labetalol—Fenoprofen—ALB—chronic obstructive pulmonary disease	4e-05	0.0273	CrCbGaD
Labetalol—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	3.98e-05	0.0012	CcSEcCtD
Labetalol—Flushing—Prednisone—chronic obstructive pulmonary disease	3.91e-05	0.00118	CcSEcCtD
Labetalol—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	3.85e-05	0.0101	CbGpPWpGaD
Labetalol—ADRB3—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	3.75e-05	0.00983	CbGpPWpGaD
Labetalol—Alopecia—Prednisone—chronic obstructive pulmonary disease	3.72e-05	0.00112	CcSEcCtD
Labetalol—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	3.69e-05	0.00111	CcSEcCtD
Labetalol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	3.69e-05	0.00111	CcSEcCtD
Labetalol—Erythema—Prednisone—chronic obstructive pulmonary disease	3.66e-05	0.0011	CcSEcCtD
Labetalol—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	3.61e-05	0.00946	CbGpPWpGaD
Labetalol—Pain—Prednisolone—chronic obstructive pulmonary disease	3.52e-05	0.00106	CcSEcCtD
Labetalol—Vision blurred—Prednisone—chronic obstructive pulmonary disease	3.45e-05	0.00104	CcSEcCtD
Labetalol—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	3.4e-05	0.00102	CcSEcCtD
Labetalol—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	3.39e-05	0.00102	CcSEcCtD
Labetalol—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	3.38e-05	0.00887	CbGpPWpGaD
Labetalol—Angioedema—Prednisone—chronic obstructive pulmonary disease	3.35e-05	0.00101	CcSEcCtD
Labetalol—Malaise—Prednisone—chronic obstructive pulmonary disease	3.3e-05	0.000996	CcSEcCtD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	3.3e-05	0.00866	CbGpPWpGaD
Labetalol—Vertigo—Prednisone—chronic obstructive pulmonary disease	3.29e-05	0.000992	CcSEcCtD
Labetalol—Syncope—Prednisone—chronic obstructive pulmonary disease	3.29e-05	0.000991	CcSEcCtD
Labetalol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	3.27e-05	0.000986	CcSEcCtD
Labetalol—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	3.22e-05	0.000971	CcSEcCtD
Labetalol—Hypertension—Prednisone—chronic obstructive pulmonary disease	3.16e-05	0.000954	CcSEcCtD
Labetalol—Discomfort—Prednisone—chronic obstructive pulmonary disease	3.08e-05	0.000929	CcSEcCtD
Labetalol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	3.03e-05	0.000914	CcSEcCtD
Labetalol—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	2.99e-05	0.000901	CcSEcCtD
Labetalol—Oedema—Prednisone—chronic obstructive pulmonary disease	2.99e-05	0.000901	CcSEcCtD
Labetalol—Shock—Prednisone—chronic obstructive pulmonary disease	2.94e-05	0.000887	CcSEcCtD
Labetalol—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	2.89e-05	0.000871	CcSEcCtD
Labetalol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	2.72e-05	0.00082	CcSEcCtD
Labetalol—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	2.68e-05	0.000809	CcSEcCtD
Labetalol—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	2.66e-05	0.00698	CbGpPWpGaD
Labetalol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	2.63e-05	0.000794	CcSEcCtD
Labetalol—Flurbiprofen—ALB—chronic obstructive pulmonary disease	2.61e-05	0.0178	CrCbGaD
Labetalol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	2.6e-05	0.00682	CbGpPWpGaD
Labetalol—Rash—Prednisolone—chronic obstructive pulmonary disease	2.59e-05	0.000782	CcSEcCtD
Labetalol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	2.59e-05	0.000781	CcSEcCtD
Labetalol—Fatigue—Prednisone—chronic obstructive pulmonary disease	2.58e-05	0.000777	CcSEcCtD
Labetalol—Headache—Prednisolone—chronic obstructive pulmonary disease	2.58e-05	0.000777	CcSEcCtD
Labetalol—ADRB1—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	2.58e-05	0.00676	CbGpPWpGaD
Labetalol—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	2.57e-05	0.00673	CbGpPWpGaD
Labetalol—Constipation—Prednisone—chronic obstructive pulmonary disease	2.56e-05	0.000771	CcSEcCtD
Labetalol—ADRB2—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	2.52e-05	0.00662	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	2.51e-05	0.00659	CbGpPWpGaD
Labetalol—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	2.46e-05	0.000743	CcSEcCtD
Labetalol—ADRB2—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	2.45e-05	0.00642	CbGpPWpGaD
Labetalol—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	2.45e-05	0.000737	CcSEcCtD
Labetalol—Nausea—Prednisolone—chronic obstructive pulmonary disease	2.44e-05	0.000737	CcSEcCtD
Labetalol—ADRB3—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	2.42e-05	0.00634	CbGpPWpGaD
Labetalol—Urticaria—Prednisone—chronic obstructive pulmonary disease	2.38e-05	0.000716	CcSEcCtD
Labetalol—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	2.36e-05	0.000713	CcSEcCtD
Labetalol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	2.36e-05	0.000713	CcSEcCtD
Labetalol—Ketoprofen—ALB—chronic obstructive pulmonary disease	2.36e-05	0.0161	CrCbGaD
Labetalol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	2.29e-05	0.006	CbGpPWpGaD
Labetalol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	2.24e-05	0.00587	CbGpPWpGaD
Labetalol—ADRB1—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	2.23e-05	0.00584	CbGpPWpGaD
Labetalol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	2.2e-05	0.000664	CcSEcCtD
Labetalol—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.15e-05	0.000647	CcSEcCtD
Labetalol—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.12e-05	0.000638	CcSEcCtD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	2.11e-05	0.00553	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	2.07e-05	0.00543	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	2.06e-05	0.0054	CbGpPWpGaD
Labetalol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.05e-05	0.000617	CcSEcCtD
Labetalol—Dizziness—Prednisone—chronic obstructive pulmonary disease	1.98e-05	0.000596	CcSEcCtD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.96e-05	0.00514	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.92e-05	0.00503	CbGpPWpGaD
Labetalol—Vomiting—Prednisone—chronic obstructive pulmonary disease	1.9e-05	0.000573	CcSEcCtD
Labetalol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.89e-05	0.00496	CbGpPWpGaD
Labetalol—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	1.89e-05	0.00496	CbGpPWpGaD
Labetalol—Rash—Prednisone—chronic obstructive pulmonary disease	1.89e-05	0.000568	CcSEcCtD
Labetalol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	1.88e-05	0.000568	CcSEcCtD
Labetalol—Headache—Prednisone—chronic obstructive pulmonary disease	1.87e-05	0.000565	CcSEcCtD
Labetalol—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.87e-05	0.00489	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	1.85e-05	0.00485	CbGpPWpGaD
Labetalol—Nausea—Prednisone—chronic obstructive pulmonary disease	1.78e-05	0.000535	CcSEcCtD
Labetalol—ADRB3—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	1.76e-05	0.00462	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	1.62e-05	0.00425	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	1.6e-05	0.0042	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	1.58e-05	0.00414	CbGpPWpGaD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.53e-05	0.00402	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.49e-05	0.00391	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.46e-05	0.00383	CbGpPWpGaD
Labetalol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	1.43e-05	0.00376	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	1.42e-05	0.00373	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	1.41e-05	0.0037	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.35e-05	0.00354	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.33e-05	0.00349	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	1.29e-05	0.00338	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.25e-05	0.00327	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	1.23e-05	0.00323	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	1.23e-05	0.00322	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	1.22e-05	0.00321	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	1.2e-05	0.00314	CbGpPWpGaD
Labetalol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	1.12e-05	0.00294	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	1.12e-05	0.00294	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	1.1e-05	0.0029	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	1.1e-05	0.00288	CbGpPWpGaD
Labetalol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	1.1e-05	0.00288	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	1.07e-05	0.00282	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	1.05e-05	0.00274	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	1.02e-05	0.00268	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1e-05	0.00262	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	9.61e-06	0.00252	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	9.5e-06	0.00249	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	9.45e-06	0.00248	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	9.4e-06	0.00247	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	9.36e-06	0.00245	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	9.34e-06	0.00245	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	9.29e-06	0.00244	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	9.21e-06	0.00242	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	8.91e-06	0.00234	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	8.58e-06	0.00225	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	8.47e-06	0.00222	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	8.43e-06	0.00221	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	8.36e-06	0.00219	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	8.25e-06	0.00216	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	8.18e-06	0.00215	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.14e-06	0.00213	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	8.09e-06	0.00212	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.03e-06	0.00211	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	7.96e-06	0.00209	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	7.66e-06	0.00201	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	7.62e-06	0.002	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	7.61e-06	0.002	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	7.49e-06	0.00196	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	7.4e-06	0.00194	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	7.32e-06	0.00192	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	7.24e-06	0.0019	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	7.23e-06	0.0019	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	7.16e-06	0.00188	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	6.97e-06	0.00183	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	6.55e-06	0.00172	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.33e-06	0.00166	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.94e-06	0.00156	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.81e-06	0.00152	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.61e-06	0.00147	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	5.57e-06	0.00146	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.49e-06	0.00144	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	5.29e-06	0.00139	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—KL—chronic obstructive pulmonary disease	5.18e-06	0.00136	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.8e-06	0.00126	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.78e-06	0.00125	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.73e-06	0.00124	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.62e-06	0.00121	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.52e-06	0.00119	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.52e-06	0.00119	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.42e-06	0.00116	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.42e-06	0.00116	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.34e-06	0.00114	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.3e-06	0.00113	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.29e-06	0.00113	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.27e-06	0.00112	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	4.22e-06	0.00111	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.2e-06	0.0011	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.13e-06	0.00108	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.04e-06	0.00106	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.92e-06	0.00103	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.91e-06	0.00103	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.88e-06	0.00102	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.75e-06	0.000985	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.74e-06	0.00098	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.67e-06	0.000963	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.47e-06	0.000911	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.31e-06	0.000867	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.23e-06	0.000848	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.07e-06	0.000806	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.01e-06	0.000789	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.86e-06	0.000749	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.84e-06	0.000744	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.73e-06	0.000715	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.6e-06	0.000683	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.55e-06	0.00067	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.54e-06	0.000665	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.5e-06	0.000655	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.48e-06	0.00065	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.32e-06	0.000608	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.31e-06	0.000606	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.3e-06	0.000605	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.3e-06	0.000604	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	2.28e-06	0.000598	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.27e-06	0.000595	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.25e-06	0.000591	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.22e-06	0.000582	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.2e-06	0.000576	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.17e-06	0.000569	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.09e-06	0.000548	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	2.08e-06	0.000545	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.06e-06	0.000541	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.02e-06	0.000529	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.92e-06	0.000502	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.87e-06	0.000492	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.72e-06	0.000451	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.7e-06	0.000445	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.69e-06	0.000443	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.66e-06	0.000435	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.62e-06	0.000424	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.6e-06	0.000419	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.58e-06	0.000415	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.58e-06	0.000413	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.54e-06	0.000405	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.51e-06	0.000396	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.47e-06	0.000385	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.42e-06	0.000372	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.39e-06	0.000365	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.37e-06	0.000359	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.34e-06	0.000352	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.3e-06	0.000342	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.3e-06	0.00034	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.27e-06	0.000334	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.24e-06	0.000325	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.21e-06	0.000318	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.11e-06	0.000292	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.09e-06	0.000286	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.02e-06	0.000268	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1e-06	0.000263	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.99e-07	0.000262	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.8e-07	0.000257	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	9.46e-07	0.000248	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	9.05e-07	0.000237	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	8.41e-07	0.000221	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	8.23e-07	0.000216	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.7e-07	0.000202	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.53e-07	0.000197	CbGpPWpGaD
